Valcyte - Revision history

Lazy at 08:17, 18 January 2025

2025-01-18T08:17:26Z

← Older revision		Revision as of 01:17, 18 January 2025
Line 14:		Line 14:
	\|toxicity_level=2		\|toxicity_level=2
	\|toxicity_explanation=The drug Valganciclovir (Valcyte) has a relatively low toxicity level. This is measured on a scale between 1 and 5, with 1 being the least toxic and 5 the most toxic. While Valganciclovir is approved by the FDA, it is currently used for the treatment of CMV infections, and its use for glioblastoma is still investigational. Its common side effects include diarrhea, nausea, and neutropenia, which is a lower-than-normal count of neutrophils, a type of white blood cell that helps fight off infections. It also has a potential risk for causing birth defects. The toxicity rating takes into account these potential side effects and the current state of research on its use in treating glioblastoma.		\|toxicity_explanation=The drug Valganciclovir (Valcyte) has a relatively low toxicity level. This is measured on a scale between 1 and 5, with 1 being the least toxic and 5 the most toxic. While Valganciclovir is approved by the FDA, it is currently used for the treatment of CMV infections, and its use for glioblastoma is still investigational. Its common side effects include diarrhea, nausea, and neutropenia, which is a lower-than-normal count of neutrophils, a type of white blood cell that helps fight off infections. It also has a potential risk for causing birth defects. The toxicity rating takes into account these potential side effects and the current state of research on its use in treating glioblastoma.
	}}		\|overview=Valganciclovir (Valcyte) is an FDA-approved anti-CMV medication that is being investigated for its potential therapeutic effects against glioblastoma, particularly in tumors that test positive for CMV proteins. Early studies suggest improved survival outcomes with long-term use, but further clinical trials are needed to validate its efficacy and optimal application in this context.}}

69.163.248.232: Updated category= to treatment_category= in TreatmentInfo template

2024-11-12T18:24:52Z

Updated category= to treatment_category= in TreatmentInfo template

← Older revision		Revision as of 11:24, 12 November 2024
Line 10:		Line 10:
	\|usefulness_rating=3		\|usefulness_rating=3
	\|notes=Valganciclovir, an anti-CMV drug, has been explored for glioblastoma treatment due to the majority of these tumors being positive for CMV proteins. Initial studies suggest a possible therapeutic benefit, especially with long-term use, but results require further validation through rigorously designed clinical trials to conclusively determine efficacy and optimal usage in glioblastoma treatment.		\|notes=Valganciclovir, an anti-CMV drug, has been explored for glioblastoma treatment due to the majority of these tumors being positive for CMV proteins. Initial studies suggest a possible therapeutic benefit, especially with long-term use, but results require further validation through rigorously designed clinical trials to conclusively determine efficacy and optimal usage in glioblastoma treatment.
	\|~~category~~=Investigational Drugs		\|treatment_category=Investigational Drugs
	\|links=		\|links=
	\|toxicity_level=2		\|toxicity_level=2
	\|toxicity_explanation=The drug Valganciclovir (Valcyte) has a relatively low toxicity level. This is measured on a scale between 1 and 5, with 1 being the least toxic and 5 the most toxic. While Valganciclovir is approved by the FDA, it is currently used for the treatment of CMV infections, and its use for glioblastoma is still investigational. Its common side effects include diarrhea, nausea, and neutropenia, which is a lower-than-normal count of neutrophils, a type of white blood cell that helps fight off infections. It also has a potential risk for causing birth defects. The toxicity rating takes into account these potential side effects and the current state of research on its use in treating glioblastoma.		\|toxicity_explanation=The drug Valganciclovir (Valcyte) has a relatively low toxicity level. This is measured on a scale between 1 and 5, with 1 being the least toxic and 5 the most toxic. While Valganciclovir is approved by the FDA, it is currently used for the treatment of CMV infections, and its use for glioblastoma is still investigational. Its common side effects include diarrhea, nausea, and neutropenia, which is a lower-than-normal count of neutrophils, a type of white blood cell that helps fight off infections. It also has a potential risk for causing birth defects. The toxicity rating takes into account these potential side effects and the current state of research on its use in treating glioblastoma.
	}}		}}

Lazy at 16:53, 27 March 2024

2024-03-27T16:53:17Z

← Older revision		Revision as of 09:53, 27 March 2024
Line 12:		Line 12:
	\|category=Investigational Drugs		\|category=Investigational Drugs
	\|links=		\|links=
			\|toxicity_level=2
			\|toxicity_explanation=The drug Valganciclovir (Valcyte) has a relatively low toxicity level. This is measured on a scale between 1 and 5, with 1 being the least toxic and 5 the most toxic. While Valganciclovir is approved by the FDA, it is currently used for the treatment of CMV infections, and its use for glioblastoma is still investigational. Its common side effects include diarrhea, nausea, and neutropenia, which is a lower-than-normal count of neutrophils, a type of white blood cell that helps fight off infections. It also has a potential risk for causing birth defects. The toxicity rating takes into account these potential side effects and the current state of research on its use in treating glioblastoma.
	}}		}}

Lazy: Created page with "{{TreatmentInfo |drug_name=Valganciclovir (Valcyte) |FDA_approval=Yes (for CMV infections) |used_for=Investigational use in glioblastoma due to potential effects against CMV positive tumors |clinical_trial_phase=Investigational, including early clinical trials |common_side_effects=Includes diarrhea, nausea, neutropenia, potential for increased risk of birth defects |OS_without=Median survival with standard treatment: 17.4 months |OS_with=Post-hoc analysis with at least s..."

2024-03-20T10:26:55Z

Created page with "{{TreatmentInfo |drug_name=Valganciclovir (Valcyte) |FDA_approval=Yes (for CMV infections) |used_for=Investigational use in glioblastoma due to potential effects against CMV positive tumors |clinical_trial_phase=Investigational, including early clinical trials |common_side_effects=Includes diarrhea, nausea, neutropenia, potential for increased risk of birth defects |OS_without=Median survival with standard treatment: 17.4 months |OS_with=Post-hoc analysis with at least s..."

New page

{{TreatmentInfo
|drug_name=Valganciclovir (Valcyte)
|FDA_approval=Yes (for CMV infections)
|used_for=Investigational use in glioblastoma due to potential effects against CMV positive tumors
|clinical_trial_phase=Investigational, including early clinical trials
|common_side_effects=Includes diarrhea, nausea, neutropenia, potential for increased risk of birth defects
|OS_without=Median survival with standard treatment: 17.4 months
|OS_with=Post-hoc analysis with at least six months of Valcyte use: median survival of 24 months, 4-year survival of 27%
|PFS_with=Not directly specified; improvements noted in selected patient analyses
|usefulness_rating=3
|notes=Valganciclovir, an anti-CMV drug, has been explored for glioblastoma treatment due to the majority of these tumors being positive for CMV proteins. Initial studies suggest a possible therapeutic benefit, especially with long-term use, but results require further validation through rigorously designed clinical trials to conclusively determine efficacy and optimal usage in glioblastoma treatment.
|category=Investigational Drugs
|links=
}}